

## Supplementary Material

**Table S1. Expressions of pathological impulsivity.** MedDRA query and behavioral subqueries used for retrieving drug-induced impulsivity.

Impulsivity expression	Preferred Terms (PT)
Pathological gambling	gambling disorder, gambling
Hypersexuality	compulsive sexual behaviour, hypersexuality, excessive masturbation, excessive sexual fantasies, libido increased, sexual activity increased, kluger-bucy syndrome
Paraphilia	erotophonophilia, exhibitionism, fetishism, frotteurism, masochism, paraphilia, pedophilia, sadism, transvestism, voyeurism, sexually inappropriate behaviour
Compulsive shopping	compulsive shopping
Hyperphagia	binge eating, food craving, hyperphagia, increased appetite
Gaming disorder	gaming disorder
Pyromania	pyromania
Kleptomania	kleptomania
Compulsive hoarding	compulsive hoarding
Excessive exercise	excessive exercise
Overwork	overwork
Poriomania	poriomania
Body-focused repetitive behaviors	compulsive cheek biting, compulsive lip biting, dermatillomania, dermatophagia, nail picking, compulsive handwashing, trichotemnomania, trichotillomania, onychophagia, thumb sucking
Stereotypy	automatism, stereotypy
Impulsivity	impulse-control disorder, impulsive behaviour, disinhibition, behavioural addiction

**Table S2. Manifestation of impulsivity in the two populations investigated.**

Pramipexole		Aripiprazole	
Gambling disorder	1345 (4.87%)	Gambling disorder	2067 (2.58%)
Hypersexuality	612 (2.22%)	Hypersexuality	1077 (1.34%)
Impulsivity	453 (1.64%)	Compulsive shopping	1029 (1.28%)
Compulsive shopping	384 (1.39%)	Hyperphagia	868 (1.08%)
Hyperphagia	334 (1.21%)	Impulsivity	730 (0.91%)
Stereotypy	87 (0.32%)	Body-focused disorder	316 (0.39%)
Paraphilia	64 (0.23%)	Compulsive hoarding	244 (0.30%)
Compulsive hoarding	26 (0.09%)	Paraphilia	78 (0.10%)
Body-focused disorder	18 (0.07%)	Stereotypy	42 (0.05%)
Excessive exercise	7 (0.03%)	Poriomania	15 (0.02%)
Kleptomania	7 (0.03%)	Kleptomania	6 (0.01%)
Gaming disorder	3 (0.01%)	Pyromania	4 (0.00%)
Poriomania	2 (0.01%)	Overwork	1 (0.00%)
Pyromania	1 (0.00%)		

**Table S3. Features of pramipexole reports.** We compared cases of pramipexole-related pathological impulsivity vs any other report recording pramipexole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.

VARIABLE	Impulsivity Reports N = 2,066		Other Reports N = 25,535		p-value
	N	%	N	%	
<b>Gender</b>					<b>&lt;0.001</b>
Woman	821	42.58	14,964	63.01	
Man	1,107	57.42	8,784	36.99	
Unknown	138	-	1,787	-	
<b>Age (years old)</b>					<b>&lt;0.001</b>
Unknown		56 (48-64) 903		67 (57-75) 8,482	
<b>Weight (Kg)</b>					<b>&lt;0.001</b>
Unknown		83 (72-95) 1,386		79 (65-95) 16,330	
<b>Outcome</b>					<b>&lt;0.001</b>
Death	40	1.94	1,883	7.37	
Life Threatening	50	2.42	713	2.79	
Disability	90	4.36	687	2.69	
Required Intervention	27	1.31	74	0.29	
Hospitalization	305	14.76	7,378	28.89	
Congenital	0	0.00	20	0.08	
Other Serious	627	30.35	6,205	24.30	
Non-Serious	927	44.87	8,575	33.58	
<b>Reporter</b>					
Consumer	1,092	56.73	10,315	44.75	
Healthcare practitioner	50	2.60	1,378	5.98	
Lawyer	29	1.51	220	0.95	
Other	380	19.74	3,366	14.60	
Pharmacist	29	1.51	1,822	7.90	
Physician	345	17.92	5,950	25.81	
Unknown	141	-	2,484	-	

**Table S4. Features of aripiprazole reports.** We compared cases of aripiprazole-related pathological impulsivity vs any other report recording aripiprazole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.

VARIABLE	Impulsivity Reports N = 3,609		Other Reports N = 76,629		p-value
	N	%	N	%	
<b>Gender</b>					<b>&lt;0.001</b>
Woman	1,624	51.41	40,454	59.28	
Man	1,535	48.59	27,792	40.72	
Unknown	450	-	8,383	-	
<b>Age (years old)</b>		40 (25-51)		41 (26-55)	<b>&lt;0.001</b>
Unknown		1,951		25,267	
<b>Weight (Kg)</b>		82 (68-104)		79 (63-98)	<b>&lt;0.001</b>
Unknown		2,876		55,594	
<b>Outcome</b>					<b>&lt;0.001</b>
Death	31	0.86	4,099	5.35	
Life Threatening	61	1.69	2,823	3.68	
Disability	483	13.38	1,868	2.44	
Required Intervention	12	0.33	280	0.37	
Hospitalization	1,205	33.39	17,921	23.39	
Congenital	0	0.00	325	0.42	
Other Serious	896	24.83	21,051	27.47	
Non-Serious	921	25.52	28,262	36.88	
<b>Reporter</b>					
Consumer	1,416	40.18	34,977	48.55	
Healthcare practitioner	173	4.91	4,146	5.76	
Lawyer	1,201	34.08	790	1.10	
Other	256	7.26	10,795	14.98	
Pharmacist	45	1.28	4,159	5.77	
Physician	433	12.29	17,173	23.84	
Unknown	85	-	4,589	-	

**Table S5. Events disproportionally reported with aripiprazole-induced impulsivity. Ordered by N.**

Event	Perc (%)	Information Component Median (95% CI) [N]
economic problem	37,85	4.28 (4.19-4.34) [1366]
obsessive-compulsive disorder	33,19	4.16 (4.07-4.23) [1198]
product use in unapproved indication	27,51	2.8 (2.69-2.87) [993]
Injury	25,10	4 (3.9-4.08) [906]
mental disorder	23,75	3.7 (3.59-3.78) [857]
suicidal ideation	23,47	2.69 (2.58-2.77) [847]
weight increased	23,19	1.83 (1.71-1.91) [837]
emotional distress	22,80	3.75 (3.63-3.83) [823]
Anxiety	21,56	2.2 (2.09-2.29) [778]
suicide attempt	21,50	2.99 (2.88-3.08) [776]
condition aggravated	20,34	2.91 (2.79-3) [734]
eating disorder	16,15	4.05 (3.92-4.15) [583]
Pain	14,35	2.45 (2.3-2.55) [518]
loss of employment	12,64	4.33 (4.18-4.44) [456]
Disability	11,42	3.79 (3.63-3.91) [412]
Anhedonia	10,94	3.75 (3.59-3.87) [395]
Bankruptcy	10,58	4.43 (4.26-4.55) [382]
Insomnia	8,04	1.13 (0.94-1.27) [290]
Divorced	7,59	4.38 (4.19-4.53) [274]
Homeless	6,93	4.37 (4.16-4.52) [250]
sexual dysfunction	6,79	3.25 (3.04-3.4) [245]
Depression	6,62	0.78 (0.57-0.94) [239]
Fatigue	6,62	0.78 (0.57-0.94) [239]
Theft	5,79	4.32 (4.09-4.48) [209]
Shoplifting	5,02	4.37 (4.12-4.54) [181]
neuropsychiatric symptoms	4,74	4.35 (4.1-4.53) [171]
Irritability	4,54	1.73 (1.47-1.91) [164]
Aggression	4,35	1.26 (1-1.45) [157]
Akathisia	4,05	0.89 (0.62-1.09) [146]
Somnolence	4,02	0.38 (0.1-0.57) [145]
Headache	4,02	0.51 (0.24-0.71) [145]
Restlessness	3,69	1.08 (0.79-1.28) [133]
Agitation	3,57	0.76 (0.47-0.97) [129]
abnormal behaviour	3,44	1.28 (0.98-1.49) [124]
Mania	3,13	1.11 (0.8-1.33) [113]
mental impairment	3,08	2.26 (1.95-2.49) [111]
sexually transmitted disease	3,05	4.24 (3.93-4.47) [110]
Hypertension	2,96	1.01 (0.69-1.24) [107]
Asthenia	2,96	0.89 (0.57-1.13) [107]
personal relationship issue	2,94	3.9 (3.58-4.13) [106]
Obesity	2,91	1.42 (1.1-1.66) [105]
weight decreased	2,72	0.79 (0.46-1.03) [98]
disturbance in attention	2,72	1.51 (1.17-1.75) [98]
feeling abnormal	2,72	0.37 (0.04-0.61) [98]
euphoric mood	2,69	3.02 (2.68-3.26) [97]
social problem	2,66	3.78 (3.45-4.03) [96]
memory impairment	2,60	1.05 (0.71-1.29) [94]
sleep disorder	2,60	1.53 (1.19-1.77) [94]
Diarrhoea	2,49	0.54 (0.19-0.8) [90]
therapeutic product effect incomplete	2,38	1.88 (1.52-2.14) [86]
depressed mood	2,36	1.68 (1.32-1.94) [85]
brain injury	2,36	3.11 (2.75-3.37) [85]
Hyperhidrosis	2,27	0.91 (0.54-1.17) [82]

Event	Perc (%)	Information Component Median (95% CI) [N]
sedation	2,24	0.72 (0.36-0.99) [81]
anger	2,19	1.39 (1.02-1.66) [79]
hallucination, auditory	2,13	0.63 (0.25-0.9) [77]
prescribed overdose	2,13	1.89 (1.52-2.17) [77]
constipation	2,11	0.83 (0.45-1.1) [76]
back pain	2,11	1.12 (0.74-1.39) [76]
blood glucose increased	2,08	0.73 (0.34-1) [75]
psychosexual disorder	2,02	4.1 (3.71-4.38) [73]
stress	2,00	1.9 (1.51-2.18) [72]
hospitalisation	2,00	0.68 (0.29-0.96) [72]
blood cholesterol increased	1,94	0.95 (0.55-1.23) [70]
arthralgia	1,88	0.78 (0.37-1.07) [68]
toxicity to various agents	1,83	0.48 (0.07-0.77) [66]
gastroesophageal reflux disease	1,83	1.97 (1.57-2.27) [66]
fear	1,83	2.1 (1.69-2.4) [66]
decreased appetite	1,77	0.75 (0.34-1.05) [64]
hypoesthesia	1,69	1.1 (0.68-1.41) [61]
antipsychotic drug level below therapeutic	1,66	3.69 (3.26-3.99) [60]
therapeutic product effect variable	1,63	4.06 (3.63-4.37) [59]
hypersomnia	1,61	1.61 (1.17-1.92) [58]
leukopenia	1,55	1.79 (1.35-2.11) [56]
drug dependence	1,55	1.88 (1.44-2.2) [56]
nightmare	1,50	1.87 (1.42-2.19) [54]
unintended pregnancy	1,50	3.71 (3.26-4.04) [54]
blood triglycerides increased	1,47	1.15 (0.69-1.48) [53]
cough	1,44	1.06 (0.6-1.39) [52]
poor quality sleep	1,36	2.25 (1.78-2.59) [49]
abdominal pain	1,36	0.74 (0.27-1.08) [49]
psychomotor hyperactivity	1,33	1.32 (0.84-1.66) [48]
paranoia	1,30	0.64 (0.15-0.98) [47]
gastrointestinal surgery	1,30	4.06 (3.57-4.41) [47]
migraine	1,27	1.2 (0.71-1.55) [46]
bipolar disorder	1,27	0.96 (0.47-1.31) [46]
mood swings	1,27	1.23 (0.74-1.58) [46]
dyslipidaemia	1,25	3.12 (2.62-3.47) [45]
amnesia	1,25	0.8 (0.31-1.16) [45]
thinking abnormal	1,19	0.86 (0.35-1.22) [43]
affective disorder	1,19	1.96 (1.45-2.32) [43]
dyspepsia	1,16	1.8 (1.28-2.16) [42]
hunger	1,16	2.14 (1.63-2.51) [42]
sleep apnoea syndrome	1,16	1.3 (0.79-1.67) [42]
dependence	1,16	3.29 (2.78-3.66) [42]
myalgia	1,14	0.55 (0.03-0.92) [41]
crying	1,14	0.81 (0.29-1.18) [41]
panic attack	1,14	1.03 (0.51-1.4) [41]
incorrect dose administered	1,14	0.69 (0.17-1.06) [41]
muscle twitching	1,11	0.79 (0.26-1.16) [40]
prescribed underdose	1,11	0.89 (0.37-1.27) [40]
personality disorder	1,08	2.66 (2.13-3.04) [39]
apathy	1,08	1.25 (0.71-1.63) [39]
alanine aminotransferase increased	1,08	1.05 (0.52-1.43) [39]
loss of personal independence in daily activities	1,05	1.12 (0.58-1.51) [38]
cognitive disorder	1,03	0.79 (0.25-1.18) [37]
low density lipoprotein increased	1,03	3.22 (2.67-3.61) [37]

**Table S6. Events disproportionally reported with pramipexole-induced impulsivity. Ordered by N.**

Event	Perc (%)	Information Component Median (95%CI) [N]
obsessive-compulsive disorder	26,77	3.47 (3.33-3.57) [553]
emotional distress	21,35	3.42 (3.26-3.54) [441]
Depression	20,67	2.43 (2.27-2.55) [427]
Pain	16,02	1.64 (1.45-1.77) [331]
Anxiety	13,79	1.93 (1.73-2.07) [285]
suicidal ideation	9,73	2.7 (2.47-2.87) [201]
weight increased	9,29	1.93 (1.7-2.11) [192]
Insomnia	7,12	0.79 (0.52-0.99) [147]
abnormal behaviour	6,73	2.52 (2.24-2.72) [139]
Somnolence	6,39	0.72 (0.43-0.92) [132]
economic problem	6,05	3.15 (2.85-3.36) [125]
Stress	5,86	2.5 (2.2-2.71) [121]
suicide attempt	5,28	2.74 (2.43-2.97) [109]
Dyskinesia	4,70	0.62 (0.28-0.86) [97]
Fear	4,65	2.95 (2.61-3.19) [96]
Injury	4,11	2.53 (2.17-2.78) [85]
Aggression	3,05	1.9 (1.48-2.2) [63]
personality change	2,66	2.93 (2.49-3.26) [55]
eating disorder	2,47	2.95 (2.49-3.28) [51]
Dependence	2,37	3.26 (2.79-3.6) [49]
hallucination, visual	2,37	0.69 (0.21-1.03) [49]
psychomotor hyperactivity	2,37	2.24 (1.76-2.58) [49]
dopamine dysregulation syndrome	2,32	2.72 (2.24-3.07) [48]
Overdose	2,27	1.27 (0.79-1.62) [47]
sleep disorder	2,23	1.07 (0.58-1.42) [46]
psychotic disorder	2,23	1.56 (1.06-1.91) [46]
Agitation	2,18	0.81 (0.32-1.17) [45]
mental disorder	2,13	2.24 (1.74-2.6) [44]

Event	Perc (%)	Information Component Median (95%CI) [N]
drug withdrawal syndrome	1,94	1.78 (1.26-2.16) [40]
drug dependence	1,94	2.34 (1.81-2.71) [40]
irritability	1,89	1.95 (1.42-2.33) [39]
drug abuse	1,89	2.46 (1.93-2.84) [39]
mania	1,84	2.02 (1.48-2.4) [38]
on and off phenomenon	1,79	0.87 (0.32-1.26) [37]
cognitive disorder	1,74	1.04 (0.48-1.43) [36]
compulsions	1,74	3.05 (2.49-3.44) [36]
sudden onset of sleep	1,74	1.61 (1.05-2) [36]
crying	1,60	1.86 (1.28-2.27) [33]
delusion	1,60	0.93 (0.35-1.34) [33]
apathy	1,45	2.7 (2.09-3.13) [30]
jealous delusion	1,45	2.58 (1.98-3.02) [30]
restlessness	1,40	0.69 (0.07-1.13) [29]
disturbance in attention	1,40	1 (0.38-1.44) [29]
hypomania	1,40	2.6 (1.98-3.04) [29]
bipolar disorder	1,36	2.2 (1.57-2.64) [28]
thinking abnormal	1,36	1.91 (1.28-2.36) [28]
withdrawal syndrome	1,31	1.35 (0.71-1.8) [27]
depressed mood	1,31	0.95 (0.31-1.4) [27]
major depression	1,26	2.69 (2.03-3.15) [26]
anger	1,21	2.04 (1.37-2.51) [25]
paranoia	1,21	1.54 (0.87-2.01) [25]
marital problem	1,11	3.3 (2.61-3.79) [23]
anhedonia	1,11	2.09 (1.39-2.58) [23]
product use in unapproved indication	1,11	0.78 (0.09-1.27) [23]
emotional disorder	1,06	1.48 (0.76-1.98) [22]
mental impairment	1,02	1.52 (0.79-2.03) [21]

**Table S7. Nodes with highest degree-centrality.**

<b>Aripiprazole</b>					
Ising		Phi		PPMI	
economic problem	24	irritability	49	overwork	97
gambling disorder	20	anxiety	47	pyromania	89
mental disorder	16	product use in unapproved indication	44	kleptomania	85
obsessive-compulsive disorder	16	suicide attempt	41	poriomania	60
compulsive shopping	15	obsessive-compulsive disorder	39	anxiety	45
Fatigue	15	depression	38	product use in unapproved indication	43
depressed mood	15	economic problem	38	suicide attempt	39
Insomnia	15	insomnia	35	obsessive-compulsive disorder	39
impulsivity	14	suicidal ideation	35	economic problem	38
emotional distress	13	asthenia	34	gambling disorder	37

<b>Pramipexole</b>					
Ising		Phi		PPMI	
gambling disorder	10	mental disorder	20	pyromania	60
emotional distress	9	agitation	18	poriomania	57
Dyskinesia	7	anxiety	14	gaming disorder	55
Anxiety	7	bipolar disorder	14	excessive exercise	48
depression	7	cognitive disorder	14	kleptomania	47
emotional disorder	6	crying	14	body-focused disorder	39
stereotypy	6	depression	14	paranoia	32
mental disorder	5	insomnia	14	emotional disorder	31
cognitive disorder	5	apathy	13	mental impairment	31
drug withdrawal syndrome	5	abnormal behaviour	12	product use in unapproved indication	30

**Table S8. Aripiprazole edges.** The ten strongest links for the three networks of aripiprazole are shown. Note that the links are undirected, therefore the two nodes may be switched.

Ising			$\varphi$			PPMI		
antipsychotic drug level below therapeutic	8.21	therapeutic product effect variable	antipsychotic drug level below therapeutic	0.99	therapeutic product effect variable	overwork	8.84	pyromania
theft	7.26	shoplifting	antipsychotic drug level below therapeutic	0.95	toxicity	kleptomania	8.33	overwork
therapeutic product effect incomplete	6.18	therapeutic product effect variable	therapeutic product effect variable	0.94	toxicity	overwork	7.08	poriomania
toxicity to various agents	6	antipsychotic drug level below therapeutic	antipsychotic drug level below therapeutic	0.93	leukopenia	kleptomania	6.96	pyromania
mental impairment	4.96	social problem	leukopenia	0.92	therapeutic product effect variable	antipsychotic drug level below therapeutic	5.95	therapeutic product effect variable
obesity	4.32	dyslipidaemia	shoplifting	0.91	theft	antipsychotic drug level below therapeutic	5.89	leukopenia
therapeutic product effect incomplete	4.16	toxicity to various agents	leukopenia	0.89	toxicity	leukopenia	5.89	therapeutic product effect variable
suicide attempt	4.16	suicidal ideation	therapeutic product effect incomplete	0.83	therapeutic product effect variable	muscle twitching	5.84	personality disorder
euphoric mood	4.1	antipsychotic drug level below therapeutic	therapeutic product effect incomplete	0.82	toxicity	antipsychotic drug level below therapeutic	5.81	toxicity to various agents
gastrooesophageal reflux disease	3.99	migraine	antipsychotic drug level below therapeutic	0.82	therapeutic product effect incomplete	therapeutic product effect variable	5.81	toxicity to various agents






**Table S9. Pramipexole edges.** The ten strongest links for the three networks of pramipexole are shown. Note that the links are undirected, therefore the two nodes may be switched.









Ising			$\phi$			PPMI		
body-focused disorder	3.11	kleptomania	emotional distress	0.56	pain	poriomania	8.82	pyromania
mental impairment	3.09	mental disorder	emotional distress	0.55	OCD	gaming disorder	8.39	pyromania
on and off phenomenon	3.05	dyskinesia	hyperphagia	0.5	weight increased	gaming disorder	7.8	poriomania
hyperphagia	2.67	weight increased	anxiety	0.48	fear	excessive exercise	7.32	pyromania
paranoia	2.66	psychotic disorder	anxiety	0.47	stress	kleptomania	7.32	pyromania
anxiety	2.61	fear	anxiety	0.43	depression	excessive exercise	6.74	poriomania
jealous delusion	2.46	marital problem	depression	0.41	stress	kleptomania	6.74	poriomania
pain	2.36	emotional distress	fear	0.41	pain	paranoia	6.39	pyromania
cognitive disorder	2.36	emotional disorder	mental disorder	0.39	mental impairment	excessive exercise	3.3	gaming disorder
depressed mood	2.3	anhedonia	dyskinesia	0.38	on and off phenomenon	gaming disorder	3.3	kleptomania




















**Table S10. Aripiprazole clusters obtained from Ising and Phi estimation.** Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similarities with Phi.



Ising	PHI	PPMI
 Hypersomnia; sleep disorder; insomnia; somnolence  Fatigue; asthenia; feeling abnormal  Constipation  Decreased appetite; weight decreased  Panic attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania  Aggression; anger; irritability  Psychomotor hyperactivity; restlessness; agitation  Abnormal behaviour  Myalgia  Drug dependence  Disturbance in attention; memory impairment  Hallucination, auditory <b>impulsivity</b> Paraphilia; stereotypy  Headache	Hypersomnia; sleep disorder; insomnia Fatigue; asthenia; feeling abnormal Constipation; <b>abdominal pain</b> Decreased appetite Panick attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania; <b>affective disorder</b> Aggression; anger Psychomotor hyperactivity; restlessness; agitation Abnormal behaviour; thinking abnormal Myalgia; <b>arthralgia; back pain</b> Drug dependence; dependence Disturbance in attention; <b>amnesia; cognitive disorder</b> Hallucination, auditory; paranoia Paraphilia; stereotypy; kleptomania; poriomania  <b>Cough</b>  Loss of personal independence in daily activities  Hospitalisation  Prescribed underdose; <b>prescribed overdose</b>	Hypersomnia; sleep disorder; insomnia Fatigue; asthenia; feeling abnormal Constipation; <b>abdominal pain</b> Decreased appetite Panick attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania; <b>affective disorder</b> Aggression; anger Psychomotor hyperactivity; restlessness; agitation Abnormal behaviour; thinking abnormal Myalgia; <b>arthralgia; back pain</b> Drug dependence; dependence Disturbance in attention; <b>amnesia; cognitive disorder</b> Hallucination, auditory; paranoia Paraphilia; stereotypy; kleptomania; poriomania; <b>overwork; pyromania</b> <b>Cough</b> Loss of personal independence in daily activities Hospitalisation Prescribed underdose; <b>incorrect dose administered</b>
 Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased	Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased	Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased; <b>hunger; sleep apnoea syndrome; gastrointestinal surgery</b>
 Fear; <b>affective disorder</b>  Personal relationship issue; social problem  Mental impairment	Fear Personal relationship issue; social problem; <b>theft; shoplifting; Disability;</b> economic problem; bankruptcy; divorced; <b>homeless; loss of employment</b> Mental impairment	Fear Personal relationship issue; social problem; <b>theft; shoplifting; Disability;</b> economic problem; bankruptcy; divorced; <b>homeless; loss of employment</b> Mental impairment







 Pain  Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety  Mental disorder  Injury; brain injury  Disability; economic problem; bankruptcy; divorced; homeless; loss of employment <b>impulsivity</b> Gambling disorder; compulsive shopping; body-focused disorder; compulsive hoarding; hypersexuality; impulsivity  Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease  Obsessive-compulsive disorder  Eating disorder; gastrointestinal surgery  Condition aggravated  Product used in unapproved indication	Pain Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety Mental disorder Injury; brain injury Gambling disorder; compulsive shopping; body-focused disorder; compulsive hoarding; hypersexuality; <b>impulsivity</b> Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease <b>Obsessive-compulsive disorder</b> Eating disorder; <b>gastrointestinal surgery</b> Condition aggravated Product used in unapproved indication	Pain Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety Mental disorder Injury; brain injury Gambling disorder; compulsive shopping; body-focused disorder; compulsive hoarding; hypersexuality Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease Eating disorder Condition aggravated Product used in unapproved indication
 <b>Theft; shoplifting</b>		
 <b>Suicidal ideation; suicide attempt</b>	<b>Suicidal ideation; suicide attempt</b>	<b>Suicidal ideation</b>
 Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents  Leukopenia  Euphoric mood	Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; <b>prescribed overdose</b> Leukopenia Euphoric mood	Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; <b>prescribed overdose</b> Leukopenia Euphoric mood
 Hunger; hyperphagia; weight increased	Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; <b>sleep apnoea syndrome</b>	Obesity; dyslipidaemia; hypertension
 Obesity; dyslipidaemia; hypertension; sleep apnoea syndrome  Akathisia  Sedation  Amnesia; cognitive disorder	Akathisia  <b>impulsivity</b> Impulsivity	Akathisia  Impulsivity
		 <b>Suicide attempt</b>  <b>Obsessive-compulsive disorder</b>


 Diarrhoea; dyspepsia; gastroesophageal reflux disease; abdominal pain  Hypoaesthesia  Poor quality sleep; nightmare  Hyperidrosis  Migraine  Muscle twitching; back pain; arthralgia  Personality disorder  Cough	Diarrhoea; dyspepsia; gastroesophageal reflux disease Hypoaesthesia Poor quality sleep; nightmare; sedation Hyperidrosis Migraine; headache Muscle twitching Personality disorder   Weight decreased  Memory impairment  Irritability	Diarrhoea; dyspepsia; gastroesophageal reflux disease Hypoaesthesia Poor quality sleep; nightmare; sedation; somnolence Hyperidrosis Migraine; headache Muscle twitching Personality disorder  Weight decreased Memory impairment Irritability  Hyperphagia; weight increased
<p><b>Isolated nodes:</b> pyromania; overwork; incorrect dose administered; prescribed overdose; prescribed underdose; poriomania; dependence; thinking abnormal; hospitalisation; paranoia; kleptomania; loss of personal independence in daily activities</p>	<p><b>Isolated nodes:</b> pyromania; overwork; incorrect dose administered</p>	

**Table S11. Pramipexole clusters obtained from Ising and Phi estimation.** Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similarities with Phi.


Ising	PHI	PPMI
<p><b>impulsivity</b> Gambling disorder; compulsive shopping</p>  Anxiety; depression; fear; emotional distress; stress  Pain  Obsessive-compulsive disorder  Suicidal ideation	<p>Gambling disorder</p> <p>Anxiety; depression; fear; emotional distress; stress; major depression</p> <p>Pain</p> <p>Obsessive-compulsive disorder</p> <p>Suicidal ideation; <b>suicide attempt</b></p>  <b>Injury</b>	<p>Gambling disorder; compulsive shopping</p> <p>Depression; fear; emotional distress; stress</p> <p>Pain</p> <p>Obsessive-compulsive disorder</p> <p>Suicidal ideation</p>
 <b>Hyperphagia; weight increased</b>	<b>Hyperphagia; weight increased</b>	<b>Hyperphagia; weight increased</b>
 <b>Sleep disorder; somnolence; insomnia; disturbance in attention</b>	<b>Sleep disorder; somnolence</b>	
 Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome <p><b>impulsivity</b> Stereotypy; impulsivity; paraphilia</p>	<p>Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome; <b>drug dependence; drug abuse</b></p> <p>Stereotypy; impulsivity; paraphilia</p>	<p>Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome; <b>drug dependence; drug abuse; dependence</b></p> <p>Stereotypy; impulsivity; paraphilia; gaming disorder; poriomania; pyromania</p>
 Drug dependence; drug abuse	<p>Aggression</p>	<p>Aggression</p>
 Aggression	<p>Compulsive hoarding</p>	<p>Compulsive hoarding</p>
<p><b>impulsivity</b> Compulsive hoarding</p>  Paranoia; hallucination, visual; psychotic disorder  Psychomotor hyperactivity; restlessness  Hypomania; mania  Eating disorder	<p>Paranoia; hallucination, visual; psychotic disorder</p> <p>Psychomotor hyperactivity; restlessness</p> <p>Hypomania; mania</p> <p>Eating disorder</p>	<p>Hallucination, visual</p> <p>Psychomotor hyperactivity; restlessness</p> <p>Eating disorder</p>
		 <b>Economic problem; abnormal behaviour</b>  <b>Injury</b>  <b>Personality change</b>

		 Somnolence  Suicide attempt
 Bipolar disorder  Mental impairment; mental disorder  Abnormal behaviour  Economic problem  Product use in unapproved indication  Injury	Bipolar disorder; emotional disorder; apathy; crying Mental impairment; mental disorder; cognitive disorder; disturbance in attention Abnormal behaviour  Overdose	Bipolar disorder; emotional disorder; apathy; crying; anxiety Mental impairment; mental disorder; cognitive disorder; disturbance in attention  Overdose
 Anhedonia; depressed mood; emotional disorder; apathy  Cognitive disorder  Overdose  Suicide attempt  Delusion		
 Agitation  Crying  Irritability	Agitation   Insomnia	Agitation  Insomnia
 Jealous delusion; paranoia; hallucination, visual; psychotic disorder <b>impulsivity</b> Hypersexuality  Marital problem  Psychomotor hyperactivity  Hypomania; mania	Jealous delusion  Hypersexuality; excessive exercise; compulsive shopping  Marital problem;  Anhedonia; depressed mood	Jealous delusion; marital problem; paranoia; psychotic disorder; delusion  Hypersexuality; excessive exercise; <b>body-focused disorder; kleptomania</b>  Hypomania; mania; anhedonia; depressed mood; major depression

	 Irritability; anger  Dependence; withdrawal syndrome  Thinking abnormal	Irritability; anger Withdrawal syndrome Thinking abnormal
<b>impulsivity</b> body-focused disorder; kleptomania	body-focused disorder; kleptomania	 Compulsions  Product use in unapproved indication  Sudden onset of sleep; <b>sleep disorder</b>
<b>Isolated nodes:</b> poriomania; compulsions; personality change; gaming disorder; eating disorder; sudden onset of sleep; restlessness; pyromania; thinking abnormal; withdrawal syndrome; excessive exercise; anger; dependence; major depression	<b>Isolated nodes:</b> poriomania; compulsions; personality change; gaming disorder	




**Figure S1. The secondary impact of aripiprazole-induced pathologic impulsivity.** The network shows the events disproportionately reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated, after rescaling them from 0 to 1.




**Figure S2. The secondary impact of aripiprazole-induced pathologic impulsivity, Ising estimation.** The network shows the events disproportionately reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Ising estimation. The layout is calculated using a spring model with, as weight, the links from the Ising.









**Figure S4. The secondary impact of aripiprazole-induced pathologic impulsivity, PPMI estimation.** The network shows the events disproportionately reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.



A




B




C

**Figure S5. The secondary impact of pramipexole-induced pathologic impulsivity.** The network shows the events disproportionately reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated, after rescaling them from 0 to 1.





**Figure S7. The secondary impact of pramipexole-induced pathologic impulsivity, Phi estimation.** The network shows the events disproportionately reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Phi estimation. The layout is calculated using a spring model with, as weight, the links from the Phi.



**Figure S8. The secondary impact of pramipexole-induced pathologic impulsivity, PPMI estimation.** The network shows the events disproportionately reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.




Figure S9. Degree centrality, pramipexole.





Figure S10. Degree centrality, aripiprazole.






Clusters PPMI

Clusters PHI


Figure S11. Sankey showing comparison between clusters in PPMI and PHI, pramipexole.



Clusters PPMI

Clusters ISING


Figure S12. Sankey showing comparison between clusters in PPMI and Ising, pramipexole.



Clusters PHI

Clusters ISING


Figure S13. Sankey showing comparison between clusters in Phi and Ising, pramipexole.



Clusters PPMI

Clusters PHI


Figure S14. Sankey showing comparison between clusters in PPMI and PHI, aripiprazole.



Clusters PPMI

Clusters ISING

Figure S15. Sankey showing comparison between clusters in PPMI and Ising, aripiprazole.



Clusters PHI

Clusters ISING

Figure S16. Sankey showing comparison between clusters in PHI and Ising, aripiprazole.